Physician profile
Megan E Solis
NPI 1649729419
$4,197.79
in general payments reported to CMS, 2019-2025
23 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.52 · 2022: $577 · 2023: $1,024 · 2024: $1,318 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,482.63 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.17 | 2021-2025 | |
| Vivus LLC | $442.13 | 2022-2025 | Qsymia, Pancreaze |
| Janssen Biotech, INC. | $311.87 | 2022-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $292.31 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $259.94 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $255.15 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.08 | 2022-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $190.59 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $167.84 | 2022-2025 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $154.51 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $147.21 | 2022-2024 | Linzess |
| Braintree Laboratories, INC. | $128.02 | 2022-2025 | Sutab, Suflave |
| Celgene Corporation | $117.58 | 2022-2024 | Zeposia |
| Pfizer INC. | $92.75 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $71.29 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $67.87 | 2022-2023 | |
| Ardelyx, INC. | $61.58 | 2022-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $18.34 | 2023 | Dificid |
| Otsuka America Pharmaceutical, INC. | $18.03 | 2024 | Rexulti |
| Intercept Pharmaceuticals, INC. | $15.89 | 2022 | |
| Valinor Pharma, LLC | $15.74 | 2025 | Movantik |
| Ethicon US, LLC | $13.91 | 2022 | |
| Genentech USA, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.